Detailed price information for Apellis Pharmaceuticals Inc (APLS-Q) from The Globe and Mail including charting and trades.

(Nasdaq: APLS) today announced that the U.S. Food and Drug Administration (FDA) has approved EMPAVELI ® (pegcetacoplan) as ...

We recently published 10 Stocks Crushing With Whopping Double-Digit Gains. Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) is one ...

Novartis and its Fabhalta may have been first to the punch in ultrarare kidney disease complement 3 glomerulopathy (C3G), but ...

Apellis Pharmaceuticals has made pipeline progress and strengthened its balance sheet. Click here to read an analysis of APLS ...

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) saw its stock soar 12% after the U.S. Food and Drug Administration (FDA) granted ...

The U.S. Food and Drug Administration has approved Apellis Pharmaceuticals' Empaveli (pegcetacoplan) as the first treatment ...

Received U.S. FDA approval for EMPAVELI® (pegcetacoplan) for treatment of patients 12 years and older with C3G and primary IC-MPGNAnnounced capped royalty purchase agreement with Sobi under which ...

JPMorgan raised the firm’s price target on Apellis (APLS) to $37 from $35 and keeps an Overweight rating on the shares. The firm updated the ...

Net Loss. Apellis reported a net loss of $57.4 million for the third quarter of 2024, compared to a net loss of $140.2 million for the same period in 2023. Cash. As of September 30, 2024, Apellis had ...

In other recent news, Apellis Pharmaceuticals reported its first-quarter earnings for 2025, revealing an earnings per share (EPS) of -$0.74, which fell short of the forecasted -$0.34.